Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Seres Therapeutics stock | 34.56

Own Seres Therapeutics stock in just a few minutes.

Posted

Fact checked

Seres Therapeutics, Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 108 staff and has a trailing 12-month revenue of around USD$23.3 million.

How to buy shares in Seres Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Seres Therapeutics. Find the stock by name or ticker symbol: MCRB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Seres Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$34.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Seres Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Seres Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Seres Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Seres Therapeutics's share price has had significant positive movement.

Its last market close was USD$34.56, which is 88.95% up on its pre-crash value of USD$3.82 and 1,271.43% up on the lowest point reached during the March crash when the shares fell as low as USD$2.52.

If you had bought USD$1,000 worth of Seres Therapeutics shares at the start of February 2020, those shares would have been worth USD$988.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$10,046.59.

Seres Therapeutics share price

Use our graph to track the performance of MCRB stocks over time.

Seres Therapeutics shares at a glance

Information last updated 2020-11-23.
Latest market close USD$34.56
52-week range USD$2.52 - USD$38.5
50-day moving average USD$32.0096
200-day moving average USD$17.4575
Wall St. target price USD$37.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.866

Buy Seres Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Seres Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Seres Therapeutics price performance over time

Historical closes compared with the close of $34.56 from 2020-11-16

1 week (2020-11-20) 0.20%
1 month (2020-10-27) 14.40%
3 months (2020-08-27) 39.92%
6 months (2020-05-27) 501.04%
1 year (2019-11-27) 786.15%
2 years (2018-11-27) 334.17%
3 years (2017-11-27) 232.95%
5 years (2015-11-27) 34.56

Seres Therapeutics financials

Revenue TTM USD$23.3 million
Gross profit TTM USD$-45,636,000
Return on assets TTM -23.27%
Return on equity TTM -115.06%
Profit margin 0%
Book value $2.062
Market capitalisation USD$3.1 billion

TTM: trailing 12 months

Shorting Seres Therapeutics shares

There are currently 4.8 million Seres Therapeutics shares held short by investors – that's known as Seres Therapeutics's "short interest". This figure is 8% down from 5.2 million last month.

There are a few different ways that this level of interest in shorting Seres Therapeutics shares can be evaluated.

Seres Therapeutics's "short interest ratio" (SIR)

Seres Therapeutics's "short interest ratio" (SIR) is the quantity of Seres Therapeutics shares currently shorted divided by the average quantity of Seres Therapeutics shares traded daily (recently around 550692.12962963). Seres Therapeutics's SIR currently stands at 8.64. In other words for every 100,000 Seres Therapeutics shares traded daily on the market, roughly 8640 shares are currently held short.

However Seres Therapeutics's short interest can also be evaluated against the total number of Seres Therapeutics shares, or, against the total number of tradable Seres Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seres Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Seres Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0886% of the tradable shares (for every 100,000 tradable Seres Therapeutics shares, roughly 89 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Seres Therapeutics.

Find out more about how you can short Seres Therapeutics stock.

Seres Therapeutics share dividends

We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.

Seres Therapeutics share price volatility

Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $2.52 up to $38.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 4.5958. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Seres Therapeutics overview

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site